SMİLE PROTOKOLÜ

Kaynaklar:

1- Chan JK, Quintanilla-Martinez L, Ferry JA, et al. , WHO Classification of Tumours of Haematopoeitic and Lymphoid Tissue, 2008Lyon, FranceInternational Agency for Research on Cancer(pg. 285-288)

2- Kwong YL. Natural killer-cell malignancies: diagnosis and treatment., Leukemia, 2005, vol. 19 12(pg. 2186-2194)

3- Ishida F, Kwong YL. Diagnosis and management of natural killer-cell malignancies., Expert Rev Hematol, 2010, vol. 3 5(pg. 593-602)

4- Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells., Cancer, 1995, vol. 76 11(pg. 2351-2356)

5- Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia., Cancer Sci, 2008, vol. 99 5(pg. 1016-1020)

6- Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma., Int J Hematol, 2003, vol. 78 2(pg. 163-167)

7- Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society., Blood, 1999, vol. 93 6(pg. 1869-1874)

8- Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study., J Clin Oncol, 2011, vol. 29 33(pg. 4410-4416)